Core Viewpoint - The pharmaceutical industry is facing multiple challenges in drug development, including lengthy clinical trial management processes, low cross-organizational collaboration efficiency, and insufficient data value extraction. The company aims to address these issues through the integration of AI large models and SaaS platforms, launching an AI as a Service (AIaaS) model that covers the entire drug lifecycle, positioning AI as a core productivity tool in clinical research [1][2]. Group 1 - The company was established in 2013 and focuses on providing end-to-end solutions for pharmaceutical research, drug safety, and commercialization through AI and big data technologies. It currently serves over 1,400 pharmaceutical companies and Contract Research Organizations (CROs), including 21 of the top 25 global pharmaceutical companies and 90 of the top 100 innovative pharmaceutical companies in China [1]. - The company has entered a phase of independent innovation and AI-driven research since 2020, upgrading from SaaS to a digital platform that breaks down barriers between organizations and software, thereby enhancing overall industry coordination [2]. - The introduction of the TrialOS and PharmaOS platforms has successfully linked various stakeholders in the pharmaceutical industry, including companies, hospitals, third-party service providers, doctors, and patients, significantly improving the efficiency of drug development and commercial performance [2]. Group 2 - With advancements in large model technology, the company has significantly expanded its AI capabilities, applying them across the entire process from new drug development to commercialization. This year, it launched a value-oriented AIaaS model that provides comprehensive intelligent support for the life sciences industry [2]. - The company has pioneered a "digital employee" system, embedding AI agents throughout the clinical research process, achieving a breakthrough from being a "productivity tool" to becoming a "productivity driver" [2]. - The strategic transformation of the company is ongoing, with plans to increase investment in AI technology research, further refine the AIaaS business model, and aggressively expand into international markets to enhance its competitiveness in innovative pharmaceutical research [2].